Inventiva IVA
NASDAQ IVA
$4.78 -0.06 (-1.24%)
As of: Sep 4, 2026 · 3:59 PM EDT

Inventiva (IVA) Income from Continuing Operations (2019 - 2021)

Inventiva (IVA) posted quarterly Income from Continuing Operations of 880664.64 for Q2 2025, up 1268.27% year-over-year from 64363.5 in Q2 2024, and up 1277.33% quarter-over-quarter from 74801.68 in Q4 2024.

Analysis

Inventiva (IVA) Income from Continuing Operations (2019 - 2021) Analysis & Trends

Inventiva's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 880664.64 for Q2 2025.

  • In Q2 2025, Income from Continuing Operations rose 1268.27% year-over-year to 880664.64; the TTM figure through Jun 2025 stood at 485166.53 (up 171.52% YoY), while the FY2025 annual figure was 411824626.98, down 100523.69% from the prior year.
  • Income from Continuing Operations for Q2 2025 stood at 880664.64, up from 74801.68 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 880664.64 in Q2 2025, with the low at 11886159.08 in Q2 2021.
  • The 5-year median for Income from Continuing Operations is 178852.68 (2022), against an average of 2024253.51.
  • The sharpest annual moves came in 2021 and 2025: Income from Continuing Operations retreated 22.57% in 2021, then jumped 1268.27% in 2025.
  • Inventiva's Income from Continuing Operations stood at 11886159.08 in 2021, then surged by 98.03% to 234656.89 in 2022, then retreated by 4.54% to 245314.3 in 2023, then jumped by 69.51% to 74801.68 in 2024, then surged by 1277.33% to 880664.64 in 2025.
  • Business Quant data shows IVA's Income from Continuing Operations at 880664.64 in Q2 2025, 74801.68 in Q4 2024, and 75382.13 in Q2 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 601.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -644.37 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 81.49 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -13.27 Mn
10 Inventiva 893.85 Mn 893.85 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2021 -11.89 Mn
Mar 31, 2021 -4.44 Mn
Dec 31, 2020 -40.11 Mn
Jun 30, 2020 -9.70 Mn
Mar 31, 2020 -7.48 Mn
Dec 31, 2019 -33.40 Mn